Variables | β2-agonists group (n = 67) | Control group (n = 67) | P-value |
---|---|---|---|
Cardiovascular complications | 6 (9%) | 9 (13%) | 0.411 |
Atrial arrhythmias | 6 (9%) | 8 (12%) | 0.572 |
Atrial fibrillation | 6 (9%) | 7 (10%) | 0.770 |
Paroxysmal supraventricular tachycardia | 0 | 1 (2%) | 0.316 |
Acute myocardial infarction | 0 | 1 (2%) | 0.316 |
Thromboembolic events | 0 | 1 (2%) | 0.316 |
Respiratory complications | 9 (13%) | 8 (12%) | 0.795 |
Pneumonia | 5 (8%) | 3 (5%) | 0.466 |
Atelectasis with bronchoscopic therapy | 4 (6%) | 4 (6%) | 1.000 |
Respiratory insufficiency requiring tracheostomy | 0 | 0 | 1.000 |
Respiratory failure requiring mechanical ventilation | 1 (2%) | 1 (2%) | 1.000 |